Oxford Cancer Analytics secures £3m seed investment led by Eka Ventures to advance cancer screening
The funding round was led by Eka Ventures and will support international studies and product development.
Oxford Cancer Analytics develops blood tests for early cancer detection using advanced proteomics and machine learning. The firm focuses on minimally invasive diagnostics to improve patient outcomes in oncology.
Oxford Cancer Analytics has secured £3m in a seed financing round led by Eka Ventures, with backing from LifeArc, MegaRobo Technologies, Oxford Technology Management, and individual investors. The company operates from Oxford and Toronto, focusing on blood-based liquid biopsy tests for early cancer detection.
The newly acquired capital will be directed towards expanding international studies and developing diagnostic products targeting lethal cancers. The firm uses high-throughput proteomics and machine learning to analyse blood samples, aiming to integrate its screening tools into existing healthcare pathways.
From the founder
"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
Peter Liu
CEO at Oxford Cancer Analytics
Investor perspective
"At Eka, we look to back transformative, data led technologies that can help shift our healthcare system to a more proactive and preventative system. OXcan’s technology has the potential to play a key part in that by enabling earlier, less expensive and more accessible cancer screening. We are also extremely focused on the expertise of the founding teams that we back and we believe Peter and Andreas have an unusual mix of deep clinical and technical expertise combined with a commercial desire to build a very large business."
Jon Coker
General Partner, Eka Ventures
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Categories
About the company
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.